(2S)-2-amino-6-[[(2S,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[[(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-octoxyoxan-2-yl]methoxy]oxane-2-carbonyl]amino]hexanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 糖脂
• 英文名称: (2S)-2-amino-6-[[(2S,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[[(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-octoxyoxan-2-yl]methoxy]oxane-2-carbonyl]amino]hexanoic acid
• 化学式: C₂₆H₄₈N₂O₁₃
• 分子量: 596.7
• InChiKey: WESCEHNVZCSPDV-AVTVCTJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  41
• 可旋转键数：
  18
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  251
• 氢给体数：
  9
• 氢受体数：
  14

文献信息

• IMPROVED PEPTIDE PHARMACEUTICALS
  申请人：EUMEDERIS PHARMACEUTICALS, INC.

  公开号：US20150307550A1

  公开（公告）日：2015-10-29

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

  本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可以改善基于肽和蛋白质的治疗药物的药理特性。
• Peptide pharmaceuticals
  申请人：EUMEDERIS PHARMACEUTICALS, INC.

  公开号：US10005817B2

  公开（公告）日：2018-06-26

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

  本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可改善基于肽和蛋白质的疗法的药物特性。
• [EN] IMPROVED PEPTIDE PHARMACEUTICALS<br/>[FR] AGENTS PHARMACEUTIQUES PEPTIDIQUES AMÉLIORÉS
  申请人：EUMEDERIS PHARMACEUTICALS INC

  公开号：WO2014081864A1

  公开（公告）日：2014-05-30

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.